Island Pharmaceuticals has commenced its phase 2b clinical trial of lead drug ISLA-101 – for potentially treating dengue ...

According to the World Health Organization (WHO), there are about 390 million dengue infections globally in a year, with more ...

Stockhead’s Fraser Palamara sits down with Island Pharmaceuticals (ASX:ILA)  CEO and managing director David Foster to get the short end of the long story on the company’s latest news.

Progress is being made in primary prevention, with several candidate dengue vaccines in late phases of development as well as improved vector control measures. Additionally, new techniques for the ...

On December 12, the Butantan Institute signed a collaboration agreement regarding an innovative model that promises to speed up the development of its US-patented dengue vaccine, which is now in final ...

The "Dengue Fever - Global Clinical Trials Review, 2024" has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an overview of the Dengue Fever Clinical trials scenario ...

ILA has dosed all subjects in the Phase 2a component of its ISLA-101 Phase 2a/b PROTECT clinical trial for dengue fever. The company said this was the first time a potential countermeasure to ...

27, 2024 (GLOBE NEWSWIRE) -- The "Dengue Fever - Global Clinical Trials ... country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs ...